Issue 1, 2017

Antibody fragments as nanoparticle targeting ligands: a step in the right direction

Abstract

Recent advances in nanomedicine have shown that dramatic improvements in nanoparticle therapeutics and diagnostics can be achieved through the use of disease specific targeting ligands. Although immunoglobulins have successfully been employed for the generation of actively targeted nanoparticles, their use is often hampered by the suboptimal characteristics of the resulting complexes. Emerging data suggest that a switch in focus from full antibodies to antibody derived fragments could help to alleviate these problems and expand the potential of antibody–nanoparticle conjugates as biomedical tools. This review aims to highlight how antibody derived fragments have been utilised to overcome both fundamental and practical issues encountered during the design and application of antibody–targeted nanoparticles.

Graphical abstract: Antibody fragments as nanoparticle targeting ligands: a step in the right direction

Article information

Article type
Perspective
Submitted
31 may 2016
Accepted
05 sen 2016
First published
16 sen 2016
This article is Open Access

All publication charges for this article have been paid for by the Royal Society of Chemistry
Creative Commons BY license

Chem. Sci., 2017,8, 63-77

Antibody fragments as nanoparticle targeting ligands: a step in the right direction

D. A. Richards, A. Maruani and V. Chudasama, Chem. Sci., 2017, 8, 63 DOI: 10.1039/C6SC02403C

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements